Triple
T17377779
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Bicycle Therapeutics |
E422484
|
entity |
| Predicate | targets |
P860
|
FINISHED |
| Object | Nectin-4/CD137 (via BT7480) |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Nectin-4/CD137 (via BT7480) | Statement: [Bicycle Therapeutics, targets, Nectin-4/CD137 (via BT7480)]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Nectin-4/CD137 (via BT7480) Context triple: [Bicycle Therapeutics, targets, Nectin-4/CD137 (via BT7480)]
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
CD20 protein
CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
-
C.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
D.
BCMA
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
-
E.
programmed cell death protein 1
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor on T cells that downregulates immune responses and promotes self-tolerance, making it a key target in cancer immunotherapy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Nectin-4/CD137 (via BT7480) Target entity description: Nectin-4/CD137 (via BT7480) refers to the tumor-targeted immune agonist mechanism of BT7480, a Bicycle Therapeutics drug candidate designed to engage Nectin-4–expressing cancer cells while activating the CD137 costimulatory receptor to stimulate anti-tumor immune responses.
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
CD20 protein
CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
-
C.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
D.
BCMA
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
-
E.
programmed cell death protein 1
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor on T cells that downregulates immune responses and promotes self-tolerance, making it a key target in cancer immunotherapy.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d889d6535c81908be333c01deaec4e |
completed | April 10, 2026, 5:25 a.m. |
| NER | Named-entity recognition | batch_69e43a6ea56c8190b56d966ccf2c91f7 |
completed | April 19, 2026, 2:14 a.m. |
Created at: April 10, 2026, 5:45 a.m.